Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost RDR vs Xalatan in ocular hypertension and primary open-angle glaucoma
2008-002122-10Phase 3Completed
- Sponsor
- RDR Pharma
- Start
- Dec 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by RDR Pharma. Primary endpoint: Change in intraocular pressure at 8 a.m. from baseline to end of trial. Started Dec 2008; status: completed.
02
Drugs
latanoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2008-002122-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002122-10.